Alvogen is a Global, High Growth Pharmaceutical Company
Focused on Developing Generic, Brand, OTC and Biosimilar Products
Therapeutic Area:
Reykjavic, Iceland
  • Alvogen offers a unique portfolio of high quality and difficult-to-make pharmaceutical products, including approximately 500 generic products on the market and 200 strategically selected development projects in the pipeline. Alvogen has the capability to produce and manufacture solid oral dosage forms, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables.
  • Alvogen’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology, in addition to a fast growing portfolio of biosimilars and OTC products.
  • Alvogen has commercial operations in more than 35 countries with regional hubs, manufacturing and R&D capabilities in the United States, South Korea, Taiwan, Romania and Iceland.
  • Alvogen offers high quality, affordable generic, brand, OTC and biosimilar medications that help reduce healthcare costs around the world.

We appreciate the Vatera team’s support of the entrepreneurial approach we have taken in building Alvogen into a high performing and high growth generic and specialty pharma company worldwide. Their network of contacts and deep sector expertise are assets for Alvogen as we strive to build the company into one of the world leaders in the generic and specialty pharma space.”

Robert Wessman
Chief Executive Officer